Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase
by
Hugo Cerecetto 1,* and Mercedes González 2,*
Hugo Cerecetto 1,* and Mercedes González 2,*
1
Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay
2
Laboratorio de Química Orgánica, Instituto de Química Biológica-Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(4), 810-838; https://doi.org/10.3390/ph3040810
Received: 1 February 2010 / Revised: 15 March 2010 / Accepted: 19 March 2010 / Published: 25 March 2010
(This article belongs to the Special Issue Tropical Medicine)
Chagas’ disease, or American trypanosomosiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the cantidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term.
View Full-Text
Keywords:
Chagas’ disease; “hit-to-lead”; drug-likeness
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Cerecetto, H.; González, M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals 2010, 3, 810-838.
Show more citation formats
